Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients;Lamivudin tedavisi uygulanmiş ve entekavir naif kronik hepatit B'li hastalarda entekavir ilaç direnci

Mikrobiyoloji Bulteni

Volumn 43, Issue 3, 2009, Pages 425-432

  Sayan, Murat ^a   Hülagü, Sadettin ^a   Çetin Akhan, Sila ^a   Şentürk, Ömer ^a   Merlç, Mellha ^a   Çekmen, Mustafa ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

Entecavir resistance; HBV; Lamivudine resistance

Indexed keywords

ANTIVIRUS AGENT; DNA DIRECTED DNA POLYMERASE; DRUG DERIVATIVE; ENTECAVIR; GUANINE; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE;

ADOLESCENT; ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CASE CONTROL STUDY; CLASSIFICATION; DRUG EFFECT; FEMALE; GENETICS; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MIDDLE AGED; MUTATION; VIROLOGY;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; GUANINE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; YOUNG ADULT;

EID: 69249199911     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Tenney DJ, Rose RE, Baidick CJ, et al. Two-year assessment of entecavir resistance in LVDe-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51: 902-11.
2. Langley DR, Walsh AW, Baldick CJ, et al. Inhibition of hepatitis B virus polymerase by entecavir. J Virol 2007; 81: 3992-4001.
3. Krastev ZA. The "return" of hepatitis B. World J Gastroenterol 2006; 12: 7081 -6.
4. Fontana, RJ. Management of patients with decompensated HBV cirrhosis. Semin Liver Dis 2003; 23: 89-100.
5. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 2006; 44: 593-606.
6. Akarsu M, Şengönül A, Tankurt E, et al. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay. J Gastroenterol Hepatol 2006; 21: 1783-8.
7. Tipples GA, Ma MM, Fischer KP, et al. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714-7.
8. Stuyver LJ, Locamini SA, Lok A, et al. and The HEP DART International Committee. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33: 751-7.
9. Zoulim F. New Antivirals. Entecavir: a new treatment option for chronic hepatitis B. J Clin Virol 2006; 36: 8-12.
10. Lok ASF, McMahon BJ. Chronic hepatitis B. AASLD Practice Guidelines. Hepatology 2007; 45: 507-39.
11. Dimou E, Papadimitropoulos V, Hadziyannis SJ. The role of entecavir in the treatment of chronic hepatitis B. Ther Clin Risk Manag 2007; 3: 1077-86.
12. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterol 2006; 130: 2039-49.
13. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006; 44: 1656-65.
14. Jardi R, Frias RF, Schaper M, et al. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients. J Viral Hepatitis 2007; 14: 835-40.
15. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to LVDe. Antimicrob Agents Chemother 2004; 48: 3498-507.
16. Baldick CJ, Tenney DJ, Mazzucco CE, et al. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology 2008; 47:1473-82.
17. Akhan SÇ, Yuluǧkural Z, Vahaboǧlu H. Response to interferon-alpha in chronic hepatitis B patients with and without precore mutant strain and effects on HBsAg titers. Chemotherapy 2007; 53 :402-6.
18. Çetin Akhan S, Gürbüz Y, Üçkardeş. H. Kronik hepatit B enfeksiyonu alan hastalarda ileri evre ile ilişkili biyokimyasal parametreler. Türkiye Klinikleri J Med Sci 2009; 29: 36-41.
19. Rüzgar M, Akhan SÇ, Vahaboǧlu H. Comparison of quantitative hepatitis B virus DNA levels in serum and liver biopsy samples of chronic hepatitis B patients. Mikrobiyol Bul 2008; 42: 283-91.
20. Avellon A and Echevarria JM. Frequency of hepatitis B virus 'a' determinant variants in unselected Spanish chronic carriers. J Med Virol 2006; 78: 24-36.
21. Colonno RJ, Rose RE, Levine SM, et al. Entecavir (ETV) resistance is not observed in nucleoside-naive subjects and is observed infrequently by week 48 in lamivudine-refractory subjects with chronic HBV infection. J Hepatol 2005; 40(Suppl 2): 173.
22. Locarnini SA. Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance. Hepatology 1998; 27: 294-7.
23. Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol 2005;32:102-12.
24. Bozdayi AM, Aslan N, Bozdayi G, et al. Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients. Arch Virol 2004; 149: 2115-29.
25. Şentürker GN, Abacioǧlu YH. S-gene sequences and genotype related restriction sites in hepatitis B virus carriers in Turkey. Infection 2004; 32: 344-9.